Clinical Trial Update: Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating high-dose methylprednisolone for COVID-19 pneumonia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• methylprednisolone (high-dose) (methylprednisolone)

Snippet

Sponsor: Azienda USL Reggio Emilia - IRCCS | Conditions: Covid19 | Phase 3 | Status: COMPLETED